Abstract | BACKGROUND: METHODS:
Rapacuronium (1.5 mg/kg) was administered to 10 healthy volunteers and 10 patients with renal failure who were undergoing non-transplant surgery, were 18-45 yr old, and were anesthetized with propofol. The adductor pollicis muscle twitch tension was monitored. Plasma samples were obtained frequently for a period of 8 h to measure the concentrations of ORG9487 and its metabolite, ORG9488. Pharmacokinetic parameters were determined using mixed-effects modeling. RESULTS: One patient was excluded from analysis because he was taking phenytoin chronically. Twitch depression at 1 min was less in patients than in healthy volunteers (median values: 92% in patients, 99% in volunteers). The times to 90% and peak twitch depression; to 10%, 25%, and 75% twitch recovery; and to 70% and 80% train-of-four ratios were similar in volunteers and patients. Rapacuronium's clearance was 32% less in patients with renal failure; in both groups, clearance decreased 0.909% per year of age compared with the value in a 30 yr old. The steady state distribution volume was 14% less in women than in men and 16% less in patients than in volunteers. For ORG9488, clearance was 85% less in patients than in volunteers. CONCLUSIONS:
|
Authors | J Szenohradszky, J E Caldwell, P M Wright, R Brown, M Lau, A M Luks, D M Fisher |
Journal | Anesthesiology
(Anesthesiology)
Vol. 90
Issue 1
Pg. 24-35
(Jan 1999)
ISSN: 0003-3022 [Print] United States |
PMID | 9915309
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Neuromuscular Nondepolarizing Agents
- Vecuronium Bromide
- rapacuronium
|
Topics |
- Adolescent
- Adult
- Female
- Humans
- Infusions, Intravenous
- Kidney Failure, Chronic
(metabolism)
- Male
- Middle Aged
- Models, Biological
- Muscle Contraction
(drug effects)
- Muscle, Skeletal
(drug effects)
- Neuromuscular Nondepolarizing Agents
(administration & dosage, pharmacokinetics, pharmacology)
- Vecuronium Bromide
(administration & dosage, analogs & derivatives, pharmacokinetics, pharmacology)
|